109 related articles for article (PubMed ID: 393377)
1. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
2. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
Wood WC; Cosimi AB; Carey RW; Kaufman SD
Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
Karakousis CP; Didolkar MS; Han T
Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
[No Abstract] [Full Text] [Related]
6. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
9. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
[TBL] [Abstract][Full Text] [Related]
12. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
Robidoux A; Gutterman JU; Bodey GP; Hersh EM
Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
14. Management of malignant melanoma.
Kroon BB; Nieweg OE
Ann Chir Gynaecol; 2000; 89(3):242-50. PubMed ID: 11079795
[TBL] [Abstract][Full Text] [Related]
15. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
[TBL] [Abstract][Full Text] [Related]
16. Effect of levamisole as a surgical adjuvant therapy for malignant melanoma.
Gonzalez RL; Spitler LE; Sagebiel RW
Cancer Treat Rep; 1978 Nov; 62(11):1703-7. PubMed ID: 365324
[TBL] [Abstract][Full Text] [Related]
17. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy.
Hamming-Vrieze O; Balm AJ; Heemsbergen WD; Hooft van Huysduynen T; Rasch CR
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):795-800. PubMed ID: 19687401
[TBL] [Abstract][Full Text] [Related]
18. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
Halpern J; Catane R; Biran S; Fuks Z
Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
[No Abstract] [Full Text] [Related]
19. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Smalley RV; Vogler WR
Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
[TBL] [Abstract][Full Text] [Related]
20. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Carbone PP; Costello W
Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
